Jean-Pierre Bronowicki - JoVE Visualize

Showing results (121-130 of 194) with videos related to

Pageof 20

Sort By:

Hepatology International|January 9, 2021

Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child-Pugh B cirrhosisJean-Frédéric Blanc, Faiza Khemissa, Jean-Pierre Bronowicki, et al.

Journal of Hepatology|April 22, 2014

Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: meta-analysis of 5 trialsJohn M Vierling, Stefan Zeuzem, Fred Poordad, et al.

JHEP Reports : Innovation in Hepatology|March 27, 2023

Impact of adjuvant sorafenib treatment after local ablation for HCC in the phase II SORAMIC trialMax Seidensticker, Osman Öcal, Kerstin Schütte, et al.

Liver International : Official Journal of the International Association for the Study of the Liver|February 23, 2016

Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational studyMasatoshi Kudo, Riccardo Lencioni, Jorge A Marrero, et al.

Antimicrobial Agents and Chemotherapy|December 17, 2014

Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosisStefan Zeuzem, Vicente Soriano, Tarik Asselah, et al.

Journal of Clinical Gastroenterology|November 2, 2018

Impact of Cytomegalovirus Infection on the Outcome of Patients With Cirrhosis: A Preliminary StudyMorgan Faivre, Vanessa Cottet, Jean-Baptiste Bour, et al.

Lancet (London, England)|December 4, 2014

Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trialEric Lawitz, Edward Gane, Brian Pearlman, et al.

The Lancet. Gastroenterology & Hepatology|June 22, 2026

Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2-3 trialPhilippe Merle, Jean-Frederic Blanc, Karine Le Malicot, et al.

Diabetes|May 27, 2018

Production of Elastin-Derived Peptides Contributes to the Development of Nonalcoholic SteatohepatitisBéatrice Romier, Corinne Ivaldi, Hervé Sartelet, et al.

Radiology|January 9, 2016

TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEONJean-François Geschwind, Masatoshi Kudo, Jorge A Marrero, et al.

Pageof 20

Showing results (121-130 of 194) with videos related to

Sort By:

Pageof 20

Hepatology International|January 9, 2021

Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child-Pugh B cirrhosisJean-Frédéric Blanc, Faiza Khemissa, Jean-Pierre Bronowicki, et al.

Journal of Hepatology|April 22, 2014

Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: meta-analysis of 5 trialsJohn M Vierling, Stefan Zeuzem, Fred Poordad, et al.

JHEP Reports : Innovation in Hepatology|March 27, 2023

Impact of adjuvant sorafenib treatment after local ablation for HCC in the phase II SORAMIC trialMax Seidensticker, Osman Öcal, Kerstin Schütte, et al.

Liver International : Official Journal of the International Association for the Study of the Liver|February 23, 2016

Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational studyMasatoshi Kudo, Riccardo Lencioni, Jorge A Marrero, et al.

Antimicrobial Agents and Chemotherapy|December 17, 2014

Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosisStefan Zeuzem, Vicente Soriano, Tarik Asselah, et al.

Journal of Clinical Gastroenterology|November 2, 2018

Impact of Cytomegalovirus Infection on the Outcome of Patients With Cirrhosis: A Preliminary StudyMorgan Faivre, Vanessa Cottet, Jean-Baptiste Bour, et al.

Lancet (London, England)|December 4, 2014

Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trialEric Lawitz, Edward Gane, Brian Pearlman, et al.

The Lancet. Gastroenterology & Hepatology|June 22, 2026

Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2-3 trialPhilippe Merle, Jean-Frederic Blanc, Karine Le Malicot, et al.

Diabetes|May 27, 2018

Production of Elastin-Derived Peptides Contributes to the Development of Nonalcoholic SteatohepatitisBéatrice Romier, Corinne Ivaldi, Hervé Sartelet, et al.

Radiology|January 9, 2016

TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEONJean-François Geschwind, Masatoshi Kudo, Jorge A Marrero, et al.

Pageof 20